ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025
[Chinese expert consensus on the diagnosis and management of nodal peripheral T-cell lymphoma (2025)].
Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral T-cell lymphomas (PTCL) are a common type of non-Hodgkin lymphoma in China, with a higher incidence compared to Western countries. Apart from extranodal NK/T-cell lymphoma, nodal PTCL is the most prevalent subtype in China. Nodal PTCL is highly aggressive with a poor prognosis. Significant differences in molecular characteristics and clinical manifestations are observed among various subtypes, and the efficacy of conventional chemotherapy is limited. In recent years, the application of targeted therapies has significantly improved outcomes for some patients and is changing treatment paradigms for initial, maintenance, and relapsed disease. Based on these advancements, the Lymphoma Expert Committee of Chinese Society of Clinical Oncology and Lymphoid Disease Group, Chinese Society of Hematology, Chinese Medical Association have organized a panel of experts to develop this consensus, aiming to promote standardized diagnosis and treatment of nodal PTCL among clinicians in China, as well as to facilitate clinical research and application of novel therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.